Argus
•
Sep 02, 2026
SUPN: Lowering target price to $42.00
Summary
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
PTCT: Lowering target price to $67.00
Sep 02, 2026
•
PTCT
CORT: Lowering target price to $119.00
Sep 02, 2026
•
CORT
ANIP: Lowering target price to $68.00
Sep 02, 2026
•
ANIP
COLL: Lowering target price to $23.00
Sep 02, 2026
•
COLL
AMPH: Raising target price to $24.00
Sep 02, 2026
•
AMPH
